MX344580B - Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. - Google Patents
Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.Info
- Publication number
- MX344580B MX344580B MX2013014805A MX2013014805A MX344580B MX 344580 B MX344580 B MX 344580B MX 2013014805 A MX2013014805 A MX 2013014805A MX 2013014805 A MX2013014805 A MX 2013014805A MX 344580 B MX344580 B MX 344580B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- treatment
- relates
- ruxolitinib
- panobinostat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una combinación que comprende: (a) Compuesto A ((R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol -1-il)-3-ciclopentilpropanonitrilo) de la Fórmula (A): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; y (b) Compuesto B (N-hidroxi-3-[4-[[[2-(2-metil-1 H-indol-3-il)-etil]-am ino]metil]fenil]-2E-2-propenamida) de la Fórmula (B): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; para uso simultáneo, concurrente, separado o secuencial, especialmente para uso en el tratamiento de enfermedades proliferativas. La invención también se refiere a composiciones farmacéuticas que comprenden tal combinación y a un método para tratar enfermedades proliferativas, en un mamífero, particularmente un humano, con tal combinación. La presente invención adicionalmente también se refiere a un empaque o producto comercial que comprende tal combinación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496750P | 2011-06-14 | 2011-06-14 | |
| US201161568717P | 2011-12-09 | 2011-12-09 | |
| PCT/US2012/042174 WO2012174061A1 (en) | 2011-06-14 | 2012-06-13 | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014805A MX2013014805A (es) | 2014-01-24 |
| MX344580B true MX344580B (es) | 2016-12-20 |
Family
ID=47357438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014805A MX344580B (es) | 2011-06-14 | 2012-06-13 | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140113919A1 (es) |
| EP (1) | EP2720696B1 (es) |
| JP (1) | JP6200884B2 (es) |
| KR (1) | KR20140056212A (es) |
| CN (1) | CN103608012A (es) |
| AU (2) | AU2012271814A1 (es) |
| BR (1) | BR112013032125A2 (es) |
| CA (1) | CA2844407A1 (es) |
| CL (1) | CL2013003577A1 (es) |
| CO (1) | CO6821954A2 (es) |
| EA (1) | EA027654B1 (es) |
| ES (1) | ES2595407T3 (es) |
| GT (1) | GT201300308A (es) |
| IL (1) | IL229766A (es) |
| MX (1) | MX344580B (es) |
| NZ (1) | NZ618367A (es) |
| PE (1) | PE20140604A1 (es) |
| PH (1) | PH12013502523A1 (es) |
| SG (1) | SG195141A1 (es) |
| WO (1) | WO2012174061A1 (es) |
| ZA (1) | ZA201308815B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| SI2782557T1 (sl) | 2011-11-23 | 2019-02-28 | Array Biopharma, Inc., | Farmacevtske formulacije |
| JP2015536964A (ja) * | 2012-11-08 | 2015-12-24 | ノバルティス アーゲー | Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
| JP6479818B2 (ja) * | 2013-05-10 | 2019-03-06 | シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード | 骨髄増殖性新生物の治療に適した化合物 |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| CN107073120B (zh) * | 2014-09-22 | 2021-03-12 | 国立研究开发法人科学技术振兴机构 | 抗流感病毒剂及抗流感病毒剂的筛选方法 |
| CZ2014773A3 (cs) * | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| HK1251655A1 (zh) | 2015-04-20 | 2019-02-01 | Tolero Pharmaceuticals, Inc. | 通过线粒体分析预测对阿伏西地的应答 |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| WO2016196991A1 (en) * | 2015-06-04 | 2016-12-08 | Children's Hospital Medical Center | Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| WO2017196261A1 (en) * | 2016-05-11 | 2017-11-16 | National University Of Singapore | Jak and hdac dual-inhibitor compounds |
| WO2017209766A1 (en) * | 2016-06-03 | 2017-12-07 | Q3 Medical Devices Limited | Stent |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP2021521170A (ja) * | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| KR20250134004A (ko) * | 2018-09-25 | 2025-09-09 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
| CA3123985A1 (en) * | 2018-12-24 | 2020-07-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| JP7717065B2 (ja) * | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| WO2021154976A1 (en) * | 2020-01-28 | 2021-08-05 | Secura Bio, Inc. | Methods of treating brain cancer with panobinostat |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| US20100069458A1 (en) * | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
| KR20150036210A (ko) * | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| ES2547916T3 (es) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
-
2012
- 2012-06-13 PH PH1/2013/502523A patent/PH12013502523A1/en unknown
- 2012-06-13 EP EP12730099.4A patent/EP2720696B1/en active Active
- 2012-06-13 ES ES12730099.4T patent/ES2595407T3/es active Active
- 2012-06-13 BR BR112013032125A patent/BR112013032125A2/pt not_active IP Right Cessation
- 2012-06-13 KR KR1020147000599A patent/KR20140056212A/ko not_active Ceased
- 2012-06-13 EA EA201490016A patent/EA027654B1/ru not_active IP Right Cessation
- 2012-06-13 NZ NZ618367A patent/NZ618367A/en not_active IP Right Cessation
- 2012-06-13 SG SG2013087002A patent/SG195141A1/en unknown
- 2012-06-13 PE PE2013002816A patent/PE20140604A1/es not_active Application Discontinuation
- 2012-06-13 MX MX2013014805A patent/MX344580B/es active IP Right Grant
- 2012-06-13 US US14/123,855 patent/US20140113919A1/en not_active Abandoned
- 2012-06-13 CN CN201280029599.0A patent/CN103608012A/zh active Pending
- 2012-06-13 WO PCT/US2012/042174 patent/WO2012174061A1/en not_active Ceased
- 2012-06-13 CA CA2844407A patent/CA2844407A1/en not_active Abandoned
- 2012-06-13 AU AU2012271814A patent/AU2012271814A1/en not_active Abandoned
- 2012-06-13 JP JP2014515936A patent/JP6200884B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-22 ZA ZA2013/08815A patent/ZA201308815B/en unknown
- 2013-12-02 IL IL229766A patent/IL229766A/en not_active IP Right Cessation
- 2013-12-11 CO CO13290159A patent/CO6821954A2/es not_active Application Discontinuation
- 2013-12-12 GT GT201300308A patent/GT201300308A/es unknown
- 2013-12-13 CL CL2013003577A patent/CL2013003577A1/es unknown
-
2017
- 2017-06-29 AU AU2017204469A patent/AU2017204469A1/en not_active Abandoned
- 2017-10-06 US US15/726,541 patent/US20180085371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103608012A (zh) | 2014-02-26 |
| EA201490016A1 (ru) | 2014-04-30 |
| HK1193045A1 (zh) | 2014-09-12 |
| NZ618367A (en) | 2016-01-29 |
| US20140113919A1 (en) | 2014-04-24 |
| CO6821954A2 (es) | 2013-12-31 |
| IL229766A (en) | 2017-10-31 |
| AU2017204469A1 (en) | 2017-07-20 |
| EA027654B1 (ru) | 2017-08-31 |
| AU2012271814A1 (en) | 2013-12-12 |
| EP2720696B1 (en) | 2016-05-25 |
| ES2595407T3 (es) | 2016-12-29 |
| GT201300308A (es) | 2017-09-28 |
| MX2013014805A (es) | 2014-01-24 |
| JP6200884B2 (ja) | 2017-09-20 |
| CA2844407A1 (en) | 2012-12-20 |
| CL2013003577A1 (es) | 2014-08-01 |
| KR20140056212A (ko) | 2014-05-09 |
| US20180085371A1 (en) | 2018-03-29 |
| JP2014517039A (ja) | 2014-07-17 |
| ZA201308815B (en) | 2014-07-30 |
| EP2720696A1 (en) | 2014-04-23 |
| BR112013032125A2 (pt) | 2016-12-13 |
| IL229766A0 (en) | 2014-01-30 |
| PE20140604A1 (es) | 2014-05-13 |
| WO2012174061A1 (en) | 2012-12-20 |
| SG195141A1 (en) | 2013-12-30 |
| PH12013502523A1 (en) | 2019-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX344580B (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| UA95281C2 (en) | Trisubstituted 1,2,4-triazoles | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| IN2015DN00528A (es) | ||
| MY172729A (en) | Pharmaceutical formulations | |
| MX2014006004A (es) | Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| MX2016004936A (es) | Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| TW200616953A (en) | Indole, indazole or indoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |